Skip to content
DataLookout
Menu

NCT07738341

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 35 words
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 1, 2026 to Jul 28, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Dose-Limiting Toxicities [DLTs] (Phase Ib)
Timeframe: Within 21 days after first dose
Objective Response Rate [ORR] (Phase II)
Timeframe: Up to approximately 2 years

Secondary (10)

Number of participants with adverse events [AEs] (Phase Ib and Phase II)
Objective Response Rate [ORR] (Phase Ib)
Duration of Response [DOR] (Phase Ib and Phase II)
Overall Survival [OS] (Phase Ib and Phase II)
Disease Control Rate [DCR] (Phase Ib and Phase II)
Show 5 moreShow less
Progression-Free Survival [PFS] (Phase Ib and Phase II)
Cmax of GB268 of GB268 (Phase Ib and Phase II)
Tmax of GB268 (Phase Ib and Phase II)
AUC of GB268 (Phase Ib and Phase II)
Number and percentage of participants with Anti-Drug Antibodies [ADAs] (Phase Ib and Phase II)

Arms and interventions

Cohort A (GB268 + Sacituzumab Tirumotecan)Experimental

GB268 (10 or 20 mg/kg Q3W intravenously \[IV\], dose selected by Safety Review Committee \[SRC\]) + Sacituzumab Tirumotecan 5 mg/kg once every 2 weeks \[Q2W\] IV. For participants with locally advanced/metastatic Triple-Negative Breast Cancer \[TNBC\] with no prior systemic therapy for advanced disease; no prior Trop-2 Antibody-Drug Conjugate \[ADC\].

Cohort B (GB268 + Nab-Paclitaxel)Experimental

GB268 (10 or 20 mg/kg Q3W IV) + Nab-Paclitaxel 260 mg/m² Day 1 Q3W IV. For participants with locally advanced/metastatic TNBC with no prior systemic therapy for advanced disease; prior adjuvant/neoadjuvant taxane allowed only if recurrence ≥12 months after last taxane dose.

Cohort E (GB268+ Datopotamab Deruxtecan)Experimental

GB268 (10 or 20 mg/kg Q3W IV) + Datopotamab Deruxtecan 6 mg/kg Day 1 Q3W IV. For participants with HR+/HER2- breast cancer who have received at least 1 line of endocrine therapy, CDK4/6i, and at least 1 line of systemic chemotherapy in the advanced setting; no prior Trop-2 ADC.

Cohort F (GB268 + Nab-Paclitaxel)Experimental

GB268 (10 or 20 mg/kg Q3W IV) + Nab-Paclitaxel 260 mg/m² Day 1 Q3W IV. For participants with HR+/HER2- breast cancer with disease progression after ≥1 line of endocrine therapy and CDK4/6i, with primary or secondary endocrine resistance; prior adjuvant/neoadjuvant taxane allowed only if recurrence ≥12 months after last taxane dose.

Cohort G (GB268 monotherapy)Experimental

GB268 monotherapy (dose not exceeding 30 mg/kg Q3W, selected by SRC) IV. For participants with HR+/HER2- breast cancer who have received prior CDK4/6i and endocrine therapy in any setting, and a TROP2 or HER2 ADC in the advanced setting.

Drugs: GB268, Nab-Paclitaxel, Datopotamab Deruxtecan (Dato-DXd), Sacituzumab Tirumotecan

Sites

1 site in 1 country

  • Cancer Hospital, Chinese Academy of Medical SciencesBeijing, China